<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACIPHEX  SPRINKLE- rabeprazole sodium capsule, delayed release </strong><br>FSC Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACIPHEX safely and effectively. See full prescribing information for ACIPHEX. <br><br>ACIPHEX<span class="Sup">®</span> (rabeprazole sodium) Delayed-Release Tablets, for oral use <br>ACIPHEX<span class="Sup">®</span> Sprinkle™ (rabeprazole sodium) Delayed-Release Capsules, for oral use <br>Initial U.S. Approval: 1999</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="80%">
<col align="right" valign="bottom" width="20%">
<tbody class="Headless">
<tr>
<td align="left">Indications and Usage, Pediatric Patients (<a href="#S1.8">1.8</a>)</td>
<td align="right">03/2013</td>
</tr>
<tr>
<td align="left">Dosage and Administration, Pediatric Patients (<a href="#S2.8">2.8</a>)</td>
<td align="right">03/2013</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#S5.3">5.3</a>)</td>
<td align="right">10/2012</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Concomitant use of ACIPHEX with Methotrexate (<a href="#S5.6">5.6</a>)</td>
<td align="right">05/2012</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ACIPHEX is a proton-pump inhibitor (PPI) indicated in adults for: </p>
<ul>
<li>Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) (<a href="#S1.1">1.1</a>)</li>
<li>Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (<a href="#S1.2">1.2</a>)</li>
<li>Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (<a href="#S1.3">1.3</a>)</li>
<li>Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> (<a href="#S1.4">1.4</a>)</li>
<li>
<span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence (<a href="#S1.5">1.5</a>)</li>
<li>Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome (<a href="#S1.6">1.6</a>)</li>
</ul>
<p class="Highlighta">In adolescent patients 12 years of age and older for: </p>
<ul><li>Short-term treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (<a href="#S1.7">1.7</a>)</li></ul>
<p class="Highlighta">In pediatric patients 1 to 11 years of age for: </p>
<ul><li>Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (<a href="#S1.8">1.8</a>)</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">ACIPHEX Delayed-Release Tablets should be swallowed whole. The tablets should not be chewed, crushed or split (<a href="#S2.10">2.10</a>). </p>
<p class="Highlighta">ACIPHEX Sprinkle Delayed-Release Capsules should be opened and the granule contents sprinkled on a spoonful of soft food or liquid (e.g. applesauce). Whole dose should be taken within 15 minutes of being sprinkled. The granules should not be chewed or crushed. Dose should be taken 30 minutes before a meal (<a href="#S2.10">2.10</a>). </p>
<table width="100%">
<col align="left" valign="top" width="75%">
<col align="left" valign="top" width="25%">
<tbody class="Headless">
<tr class="Botrule First">
<td align="left">
<span class="Bold">Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) </span>(<a href="#S2.1">2.1</a>)</td>
<td align="left">20 mg once daily</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> </span>(<a href="#S2.2">2.2</a>)</td>
<td align="left">20 mg once daily</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults </span>(<a href="#S2.3">2.3</a>)</td>
<td align="left">20 mg once daily</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> </span>(<a href="#S2.4">2.4</a>)</td>
<td align="left">20 mg once daily after morning meal</td>
</tr>
<tr><td align="left" colspan="2">
<span class="Bold"><span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence </span>(<a href="#S2.5">2.5</a>)</td></tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Three Drug Regimen:</span><br>ACIPHEX 20 mg<br>Amoxicillin 1000 mg<br>Clarithromycin 500 mg</td>
<td align="left"><span class="Italics">All three medications should be taken twice daily with morning and evening meals for 7 days</span></td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome </span>(<a href="#S2.6">2.6</a>)</td>
<td align="left">Starting dose 60 mg once daily, then adjust to patient needs</td>
</tr>
<tr class="Botrule">
<td align="left">
<span class="Bold">Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescents 12 Years of Age and Older </span>(<a href="#S2.7">2.7</a>)</td>
<td align="left">20 mg once daily</td>
</tr>
<tr class="Botrule Last">
<td align="left">
<span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in 1 to 11 Year Olds </span>(<a href="#S2.8">2.8</a>)</td>
<td align="left">Less than 15 kg: 5 mg once daily <span class="Italics">(with the option to increase to 10 mg once daily)</span> 15 kg or greater: 10 mg once daily</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul>
<li>Delayed-Release Tablets: 20 mg (<a href="#S3">3</a>)</li>
<li>Delayed-Release Capsules: 5 mg and 10 mg (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rabeprazole (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Symptomatic response to therapy with rabeprazole does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span> (<a href="#S5.1">5.1</a>)</li>
<li>Use with warfarin: monitor for increases in INR and prothombin time (<a href="#S5.2">5.2</a>)</li>
<li>PPI therapy may be associated with increased risk of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (<a href="#S5.3">5.3</a>)</li>
<li>Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine (<a href="#S5.4">5.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> has been reported rarely with prolonged treatment with PPIs (<a href="#S5.5">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>In the adult studies (4 to 8 weeks), adverse reactions that occurred at a rate greater than 2% and greater than placebo included <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (<a href="#S6.1">6.1</a>).</li>
<li>In studies of pediatric and adolescent patients (ages 1 to 16 years, and up to 36 weeks exposure) adverse reactions that occurred at a rate of ≥5% of patients included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#S6.1">6.1</a>).</li>
</ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span></span> </p>
</div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times have been reported with concomitant use with warfarin. Patients need to be monitored (<a href="#S7.2">7.2</a>)</li>
<li>Rabeprazole has been shown to inhibit cyclosporine metabolism <span class="Italics">in vitro</span> (<a href="#S7.3">7.3</a>)</li>
<li>ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin) (<a href="#S7.4">7.4</a>)</li>
<li>ACIPHEX may reduce the plasma levels of atazanavir (<a href="#S7.4">7.4</a>)</li>
<li>Methotrexate: ACIPHEX may increase serum level of methotrexate (<a href="#S7.7">7.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Studies conducted do not support the use of ACIPHEX for the treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients younger than 1 year of age (<a href="#S8.4">8.4</a>).</li>
<li>The safety and efficacy of ACIPHEX for the other adult indications have not been established for pediatric patients (<a href="#S8.4">8.4</a>).</li>
</ul></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 9/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence in Adults</a></h2>
<h2><a href="#section-1.6" class="toc">1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</a></h2>
<h2><a href="#section-1.7" class="toc">1.7 Short-term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescent Patients 12 Years of Age and Older</a></h2>
<h2><a href="#section-1.8" class="toc">1.8 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence in Adults</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Short-term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescent Patients 12 Years of Age and Older</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</a></h2>
<h2><a href="#section-2.9" class="toc">2.9 Elderly, Renal and Hepatic Impaired Patients</a></h2>
<h2><a href="#section-2.10" class="toc">2.10 Administration Recommendations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Concomitant Use with Warfarin</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Concomitant Use of ACIPHEX with Methotrexate</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs Metabolized by CYP450</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Warfarin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Cyclosporine</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Compounds Dependent on Gastric pH for Absorption</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Drugs Metabolized by CYP2C19</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Combined Administration with Clarithromycin</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Methotrexate</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Clopidogrel</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Gender</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Long-term Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 <span class="Italics">Helicobacter pylori</span> Eradication in Patients with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span> or Symptomatic Non-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Disease in Adults</a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</a></h2>
<h2><a href="#section-13.7" class="toc">14.7 Pediatric <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">ACIPHEX is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">ACIPHEX is indicated for maintaining healing and reduction in relapse rates of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms in patients with erosive or ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> Maintenance). Controlled studies do not extend beyond 12 months.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">ACIPHEX is indicated for the treatment of daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms associated with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</h2>
<p class="First">ACIPHEX is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. Most patients heal within four weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.5"></a><a name="section-1.5"></a><p></p>
<h2>1.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence in Adults</h2>
<p class="First">ACIPHEX in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> disease (active or history within the past 5 years) to eradicate <span class="Italics">H. pylori</span>. Eradication of <span class="Italics">H. pylori</span> has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> recurrence [<span class="Italics">see <a href="#S14.5">Clinical Studies (14.5)</a></span> and <span class="Italics"><a href="#S2.5">Dosage and Administration (2.5)</a></span>].</p>
<p>In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [<span class="Italics">see <a href="#S12.2">Clinical Pharmacology (12.2)</a></span> and the clarithromycin package insert<span class="Italics">, <a href="#S12.2">Clinical Pharmacology (12.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.6"></a><a name="section-1.6"></a><p></p>
<h2>1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</h2>
<p class="First">ACIPHEX is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.7"></a><a name="section-1.7"></a><p></p>
<h2>1.7 Short-term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescent Patients 12 Years of Age and Older</h2>
<p class="First">ACIPHEX is indicated for treatment of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in adolescents 12 years of age and above for up to 8 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.8"></a><a name="section-1.8"></a><p></p>
<h2>1.8 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ACIPHEX is indicated for treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in children 1 to 11 years of age for up to 12 weeks.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily for four to eight weeks [<span class="Italics">see <a href="#S1.1">Indications and Usage (1.1)</a></span>]. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily [<span class="Italics">see <a href="#S1.2">Indications and Usage (1.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily for 4 weeks [<span class="Italics">see <a href="#S1.3">Indications and Usage (1.3)</a></span>]. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. The recommended adolescent dosing is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily for 8 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</h2>
<p class="First">The recommended adult oral dose is one ACIPHEX 20 mg Delayed-Release tablet to be taken once daily after the morning meal for a period up to four weeks [<span class="Italics">see <a href="#S1.5">Indications and Usage (1.5)</a></span>]. Most patients with <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> heal within four weeks. A few patients may require additional therapy to achieve healing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 <span class="Italics">Helicobacter pylori</span> Eradication to Reduce the Risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Recurrence in Adults</h2>
<a name="table1"></a><table width="75%">
<caption><span>TABLE 1 THREE DRUG REGIMEN<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<tfoot>
<tr class="First Last"><td align="left" colspan="3" valign="top">All three medications should be taken twice daily with the morning and evening meals.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>It is important that patients comply with the full 7-day regimen [<span class="Italics">see <a href="#S14.5">Clinical Studies (14.5)</a></span>].</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">ACIPHEX Delayed-Release Tablet</td>
<td class="Rrule" align="center">20 mg</td>
<td class="Rrule" align="center">Twice Daily for 7 Days</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Amoxicillin</td>
<td class="Rrule" align="center">1000 mg</td>
<td class="Rrule" align="center">Twice Daily for 7 Days</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Clarithromycin</td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">Twice Daily for 7 Days</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</h2>
<p class="First">The dosage of ACIPHEX in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with ACIPHEX for up to one year.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Short-term Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescent Patients 12 Years of Age and Older</h2>
<p class="First">The recommended oral dose for adolescents 12 years of age and older is one 20 mg Delayed-Release Tablet once daily for up to 8 weeks [<span class="Italics">see <a href="#S8.4">Use in Specific Populations (8.4)</a></span> and <span class="Italics"><a href="#S14.7">Clinical Studies (14.7)</a></span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.8"></a><a name="section-2.8"></a><p></p>
<h2>2.8 Treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dosage of ACIPHEX Sprinkle for pediatric patients 1 to 11 years of age by body weight is:</span></p>
<ul>
<li>Less than 15 kg: 5 mg once daily for up to 12 weeks with the option to increase to 10 mg if inadequate response [<span class="Italics">see <a href="#S14.7">Clinical Studies (14.7)</a></span>].</li>
<li>15 kg or more: 10 mg once daily for up to 12 weeks [<span class="Italics">see <a href="#S14.7">Clinical Studies (14.7)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.9"></a><a name="section-2.9"></a><p></p>
<h2>2.9 Elderly, Renal and Hepatic Impaired Patients</h2>
<p class="First">No dosage adjustment is necessary in elderly patients, in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Administration of rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on rabeprazole in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, caution should be exercised in those patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.10"></a><a name="section-2.10"></a><p></p>
<h2>2.10 Administration Recommendations</h2>
<a name="table2"></a><table width="75%">
<caption><span>TABLE 2 ADMINISTRATION RECOMMENDATIONS</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Formulation</th>
<th class="Rrule" align="center">Population</th>
<th class="Rrule" align="center">Instructions</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Delayed-Release Tablet</td>
<td class="Rrule" align="left">Adults and adolescents 12 years of age and older</td>
<td class="Rrule" align="left">Swallow tablets whole. Do not chew, crush or split tablets.<br>Tablets can be taken with or without food.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Delayed-Release Capsule</td>
<td class="Rrule" align="left">Pediatric patients 1 to 11 years of age</td>
<td class="Rrule" align="left">The dose should be taken 30 minutes before a meal.<br>The granules should not be chewed or crushed. Open capsule and sprinkle entire contents on a small amount of soft food (e.g. applesauce, fruit or vegetable based baby food, or yogurt) or empty contents into a small amount of liquid (e.g. infant formula, apple juice, or pediatric electrolyte solution). The whole dose should be taken within 15 minutes of preparation.<br>Food or liquid should be at or below room temperature. Do not store mixture for future use.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ACIPHEX Delayed-Release Tablets are provided in strength of 20 mg.</p>
<p>ACIPHEX Sprinkle Delayed-Release Capsules are provided in strengths of 5 and 10 mg. The 5 mg strength is a transparent blue and opaque white No. 2 capsule. The cap of the capsule is imprinted with "↑" and the body is imprinted with "ACX 5mg". The 10 mg strength is a transparent yellow and opaque white No. 2 capsule. The cap of the capsule is imprinted with "↑" and the body is imprinted with "ACX 10mg".</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Rabeprazole is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to rabeprazole, substituted benzimidazoles or to any component of the formulation.</p>
<p>For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX, refer to the <span class="Italics">Contraindications</span> section of their package inserts.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">Gastric Malignancy</span></h2>
<p class="First">Symptomatic response to therapy with rabeprazole does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</p>
<p>Patients with healed <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were treated for up to 40 months with rabeprazole and monitored with serial gastric biopsies. Patients without <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (221 of 326 patients) had no clinically important pathologic changes in the gastric mucosa. Patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline (105 of 326 patients) had mild or moderate <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the gastric body or mild <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the gastric antrum. Patients with mild grades of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the gastric body tended to change to moderate, whereas those graded moderate at baseline tended to remain stable. Patients with mild grades of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in the gastric antrum tended to remain stable. At baseline 8% of patients had <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of glands in the gastric body and 15% had <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> in the gastric antrum. At endpoint, 15% of patients had <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of glands in the gastric body and 11% had <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> in the gastric antrum. Approximately 4% of patients had intestinal <span class="product-label-link" type="condition" conceptid="4070551" conceptname="Metaplasia">metaplasia</span> at some point during follow-up, but no consistent changes were seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Concomitant Use with Warfarin</h2>
<p class="First">Steady state interactions of rabeprazole and warfarin have not been adequately evaluated in patients. There have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving a proton pump inhibitor and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients treated with a proton pump inhibitor and warfarin concomitantly may need to be monitored for increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Published observational studies suggest that PPI therapy like ACIPHEX may be associated with an increased risk of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, especially in hospitalized patients. This diagnosis should be considered for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>].</span></p>
<p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with ACIPHEX, refer to <span class="Italics">Warnings and Precautions</span> sections of those package inserts.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></h2>
<p class="First">Several published observational studies in adults suggest that PPI therapy may be associated with an increased risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> should be managed according to established treatment guidelines [<span class="Italics">see <a href="#S2">Dosage and Administration (2)</a></span> and <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. In most patients, treatment of <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> required magnesium replacement and discontinuation of the PPI.</p>
<p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [<span class="Italics">see <a href="#S6.2">Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Concomitant Use of ACIPHEX with Methotrexate</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; <span class="Italics">see methotrexate prescribing information</span>) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [<span class="Italics">see <a href="#S7.7">Drug Interactions (7.7)</a></span>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Worldwide, over 2900 patients have been treated with rabeprazole in Phase II-III clinical trials involving various dosages and durations of treatment.</p>
<p>Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Adults</span></p>
<p>The data described below reflect exposure to ACIPHEX in 1064 adult patients exposed for up to 8 weeks. The studies were primarily placebo- and active-controlled trials in adult patients with Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>), <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> and <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span>. The population had a mean age of 53 years (range 18-89 years) and had a ratio of approximately 60% male: 40% female. The racial distribution was 86% Caucasian, 8% African American, 2% Asian and 5% other. Most patients received either 10 mg, 20 mg or 40 mg/day of ACIPHEX.</p>
<p>An analysis of adverse reactions appearing in ≥2% of ACIPHEX patients (n=1064) and with a greater frequency than placebo (n=89) in controlled North American and European acute treatment trials, revealed the following adverse reactions: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (3% vs. 1%), <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> (3% vs. 2%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (3% vs. 1%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (2% vs. 1%), and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (2% vs. 1%).</p>
<p>Three long-term maintenance studies consisted of a total of 740 adult patients; at least 54% of adult patients were exposed to rabeprazole for 6 months and at least 33% were exposed for 12 months. Of the 740 adult patients, 247 (33%) and 241 (33%) patients received 10 mg and 20 mg of ACIPHEX, respectively, while 169 (23%) patients received placebo and 83 (11%) received omeprazole.</p>
<p>The safety profile of rabeprazole in the maintenance studies in adults was consistent with what was observed in the acute studies.</p>
<p>Other adverse reactions seen in controlled clinical trials, which do not meet the above criteria (≥2% of ACIPHEX treated patients and greater than placebo) and for which there is a possibility of a causal relationship to rabeprazole, include the following: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, hepatic enzyme increase, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Combination Treatment with Amoxicillin and Clarithromycin:</span> In clinical trials using combination therapy with rabeprazole plus amoxicillin and clarithromycin (RAC), no adverse reactions unique to this drug combination were observed. In the U.S. multicenter study, the most frequently reported drug related adverse reactions for patients who received RAC therapy for 7 or 10 days were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (8% and 7%) and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (6% and 10%), respectively.</p>
<p>No clinically significant laboratory abnormalities particular to the drug combinations were observed.</p>
<p>For more information on adverse reactions or laboratory changes with amoxicillin or clarithromycin, refer to their respective package prescribing information, <span class="Italics">Adverse Reactions</span> section.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Pediatric</span></p>
<p>In a multicenter, open-label study of adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> or endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, the adverse event profile was similar to that of adults. The adverse reactions reported without regard to relationship to ACIPHEX that occurred in ≥2% of 111 patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (9.9%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4.5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4.5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3.6%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3.6%). The related reported adverse reactions that occurred in ≥2% of patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.4%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.8%). There were no adverse reactions reported in this study that were not previously observed in adults.</p>
<p>In a two-part, randomized, multicenter, double-blind, parallel-group study, 127 pediatric patients 1 to 11 years of age with endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> received either 5 mg or 10 mg (&lt;15 kg body weight) or 10 mg or 20 mg (&gt;15 kg body weight) rabeprazole. In this study, some patients were exposed to rabeprazole for 36 weeks. Adverse reactions that occurred in &gt;5% of patients included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5%). There were no adverse reactions reported in this study that were not previously observed in trials of adolescents and adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of ACIPHEX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>; <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>; <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>; <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; bullous and other <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruptions</span> of the skin; severe dermatologic reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (some fatal), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonia</span>; interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>; TSH elevations; bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>; <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> and <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. In addition, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been reported. Increases in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time/INR in patients treated with concomitant warfarin have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs Metabolized by CYP450</h2>
<p class="First">Rabeprazole is metabolized by the cytochrome P450 (CYP450) drug metabolizing enzyme system. Studies in healthy subjects have shown that rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP450 system, such as warfarin and theophylline given as single oral doses, diazepam as a single intravenous dose, and phenytoin given as a single intravenous dose (with supplemental oral dosing). Steady state interactions of rabeprazole and other drugs metabolized by this enzyme system have not been studied in patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Warfarin</h2>
<p class="First">There have been reports of increased INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving proton pump inhibitors, including rabeprazole, and warfarin concomitantly. Increases in INR and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time may lead to abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Cyclosporine</h2>
<p class="First"><span class="Italics">In vitro</span> incubations employing human liver microsomes indicated that rabeprazole inhibited cyclosporine metabolism with an IC<span class="Sub">50</span> of 62 micromolar, a concentration that is over 50 times higher than the C<span class="Sub">max</span> in healthy volunteers following 14 days of dosing with 20 mg of rabeprazole. This degree of inhibition is similar to that by omeprazole at equivalent concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Compounds Dependent on Gastric pH for Absorption</h2>
<p class="First">Rabeprazole produces sustained inhibition of gastric acid secretion. An interaction with compounds which are dependent on gastric pH for absorption may occur due to the magnitude of acid suppression observed with rabeprazole. For example, in normal subjects, co-administration of rabeprazole 20 mg QD resulted in an approximately 30% decrease in the bioavailability of ketoconazole and increases in the AUC and C<span class="Sub">max</span> for digoxin of 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</p>
<p>Concomitant use of atazanavir and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Drugs Metabolized by CYP2C19</h2>
<p class="First">In a clinical study in Japan evaluating rabeprazole in adult patients categorized by CYP2C19 genotype (n=6 per genotype category), gastric acid suppression was higher in poor metabolizers as compared to extensive metabolizers. This could be due to higher rabeprazole plasma levels in poor metabolizers. Whether or not interactions of rabeprazole sodium with other drugs metabolized by CYP2C19 would be different between extensive metabolizers and poor metabolizers has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Combined Administration with Clarithromycin</h2>
<p class="First">Combined administration consisting of rabeprazole, amoxicillin, and clarithromycin resulted in increases in plasma concentrations of rabeprazole and 14-hydroxyclarithromycin [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
<p>Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [<span class="Italics">see Warnings and Precautions in prescribing information for clarithromycin</span>]. Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [<span class="Italics">see Contraindications in prescribing information for clarithromycin</span>] [<span class="Italics">see Drug Interactions in prescribing information for amoxicillin</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.7"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Methotrexate</h2>
<p class="First">Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; <span class="Italics">see methotrexate prescribing information</span>) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted [<span class="Italics">see <a href="#S5.6">Warnings and Precautions (5.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.8"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Clopidogrel</h2>
<p class="First">Concomitant administration of rabeprazole and clopidogrel in healthy subjects had no clinically meaningful effect on exposure to the active metabolite of clopidogrel [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>]. No dose adjustment of clopidogrel is necessary when administered with an approved dose of ACIPHEX.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>There are no adequate and well-controlled studies with ACIPHEX in pregnant women. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was seen in animal reproduction studies with rabeprazole at 13 and 8 times the human exposure at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, in rats and rabbits, respectively. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Embryo-fetal developmental studies have been performed in rats at intravenous doses of rabeprazole up to 50 mg/kg/day (plasma AUC of 11.8 μg∙hr/mL, about 13 times the human exposure at the recommended oral dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) and rabbits at intravenous doses up to 30 mg/kg/day (plasma AUC of 7.3 μg∙hr/mL, about 8 times the human exposure at the recommended oral dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) and have revealed no evidence of harm to the fetus due to rabeprazole.</p>
<p>Administration of rabeprazole to rats in late gestation and during lactation at an oral dose of 400 mg/kg/day (about 195-times the human oral dose based on mg/m<span class="Sup">2</span>) resulted in decreases in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of the pups.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if ACIPHEX is excreted in human milk; however, rabeprazole is present in rat milk. Because many drugs are excreted in milk, caution should be exercised when ACIPHEX is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescent Patients Greater or Equal to 12 Years of Age</span></p>
<p>In a multicenter, randomized, open-label, parallel-group study, 111 adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, or suspected or endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were randomized and treated with either ACIPHEX 10 mg or ACIPHEX 20 mg once daily for up to 8 weeks for the evaluation of safety and efficacy. The adverse event profile in adolescent patients was similar to that of adults. The related reported adverse reactions that occurred in ≥2% of patients were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (5.4%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.8%). There were no adverse reactions reported in these studies that were not previously observed in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</span></p>
<p>The use of ACIPHEX for treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients 1 to 11 years of age is supported by a randomized, multicenter, double-blind clinical trial which evaluated two dose levels of rabeprazole in 127 pediatric patients with endoscopic and histologic evidence of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> prior to study treatment. Dosing was determined by body weight: patients weighing 6.0 to 14.9 kg received either 5 or 10 mg and those weighing 15.0 kg or more received 10 or 20 mg of ACIPHEX Sprinkle daily. After 12 weeks of rabeprazole treatment, 81% of patients demonstrated esophageal mucosal healing on endoscopic assessment. In patients who had esophageal mucosal healing at 12 weeks and elected to continue for 24 more weeks of rabeprazole, 90% retained esophageal mucosal healing at 36 weeks. No prespecified formal hypothesis testing for evaluation of efficacy was conducted. The absence of a placebo group does not allow assessment of sustained efficacy through 36 weeks. There were no adverse reactions reported in this study that were not previously observed in adolescents or adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Infants 1 to 11 Months of Age</span></p>
<p>Studies conducted do not support the use of ACIPHEX Sprinkle for the treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in pediatric patients younger than 1 year of age.</p>
<p>In a randomized, multicenter, placebo-controlled withdrawal trial, infants 1 to 11 months of age with a clinical diagnosis of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, or suspected or endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, were treated up to 8 weeks in two treatment periods. In the first treatment period (open-label), 344 infants received 10 mg of ACIPHEX Sprinkle for up to 3 weeks. Infants with clinical response were then eligible to enter the second treatment period, which was double-blind and randomized. Two hundred sixty-eight infants were randomized to receive either placebo or 5 mg or 10 mg ACIPHEX Sprinkle.</p>
<p>This study did not demonstrate efficacy based on assessment of frequency of <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span> and weight-for-age Z-score. Adverse reactions that occurred in ≥5% of patients in any treatment group and with a higher rate than placebo included <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (7%) and increased serum gastrin levels (5%). There were no adverse reactions reported in this study that were not previously observed in adolescents and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.4"></a><p></p>
<p class="First"><span class="Italics">Neonates</span> &lt;<span class="Italics">1 Month and Preterm Infants</span> &lt;<span class="Italics">44 Weeks Corrected Gestational Age</span></p>
<p>Use of ACIPHEX Sprinkle in neonates is strongly discouraged at this time for the treatment of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>, based on the risk of prolonged acid suppression and lack of demonstrated safety and effectiveness in neonates.</p>
<p>Based on population pharmacokinetic analysis, the median (range) for the apparent clearance (CL/F) was 1.05 L/h (0.0543-3.44 L/h) in neonates and 4.46 L/h (0.822-12.4 L/h) in patients 1 to 11 months of age following once daily administration of oral ACIPHEX Sprinkle.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of ACIPHEX, 19% were 65 years and over, while 4% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Gender</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal ulcer</span> and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> healing rates in women are similar to those in men. Adverse reactions and laboratory test abnormalities in women occurred at rates similar to those in men.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Bold">Because strategies for the management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of any drug.</span> There has been no experience with large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with rabeprazole. Seven reports of accidental overdosage with rabeprazole have been received. The maximum reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> was 80 mg. There were no clinical signs or symptoms associated with any reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients with Zollinger-Ellison syndrome have been treated with up to 120 mg rabeprazole QD. No specific antidote for rabeprazole is known. Rabeprazole is extensively protein bound and is not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.</p>
<p>Single oral doses of rabeprazole at 786 mg/kg and 1024 mg/kg were lethal to mice and rats, respectively. The single oral dose of 2000 mg/kg was not lethal to dogs. The major symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">labored respiration</span>, lateral or prone position and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> in mice and rats and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">watery diarrhea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> in dogs.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in ACIPHEX (rabeprazole sodium) Delayed-Release Tablets and in ACIPHEX Sprinkle (rabeprazole sodium) Delayed-Release Capsules is rabeprazole sodium, which is a proton pump inhibitor. It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1<span class="Italics">H</span>–benzimidazole sodium salt. It has an empirical formula of C<span class="Sub">18</span>H<span class="Sub">20</span>N<span class="Sub">3</span>NaO<span class="Sub">3</span>S and a molecular weight of 381.42. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is:</p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">FIGURE 1</td></tr>
<tr><td align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-01.jpg"></td></tr>
</tbody>
</table>
<p>ACIPHEX is available for oral administration as Delayed-Release, enteric-coated tablets containing 20 mg of rabeprazole sodium. ACIPHEX Sprinkle is available for oral administration as 5 mg and 10 mg rabeprazole sodium Delayed-Release Capsules containing enteric coated granules.</p>
<p>Inactive ingredients of the 20 mg tablet are carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide. Iron oxide yellow is the coloring agent for the tablet coating. Iron oxide red is the ink pigment.</p>
<p>ACIPHEX Sprinkle Delayed-Release Capsules contain granules of rabeprazole sodium in a hard hypromellose capsule. Inactive ingredients are colloidal silicon dioxide, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, potassium chloride, FD&amp;C Blue No. 2 Aluminum Lake (in the 5 mg capsule), FD&amp;C Yellow, No. 6 (in the 10 mg capsule), and gray printing ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H<span class="Sup">+</span>, K<span class="Sup">+</span>ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion.</p>
<p>In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied <span class="Italics">in vitro</span>, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> with a half-life of 90 seconds.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Antisecretory Activity</span></p>
<p>The antisecretory effect begins within one hour after oral administration of 20 mg ACIPHEX. The median inhibitory effect of ACIPHEX on 24 hour gastric acidity is 88% of maximal after the first dose. ACIPHEX 20 mg inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively, and increases the percent of a 24-hour period that the gastric pH&gt;3 from 10% to 65% (see table below). This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1-2 hours) reflects the sustained inactivation of the H<span class="Sup">+</span>, K<span class="Sup">+</span>ATPase.</p>
<a name="table3"></a><table width="75%">
<caption><span>TABLE 3 GASTRIC ACID PARAMETERS ACIPHEX VERSUS PLACEBO AFTER 7 DAYS OF ONCE DAILY DOSING</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Parameter</th>
<th class="Rrule" align="center" valign="middle">ACIPHEX<br>(20 mg QD)</th>
<th class="Rrule" align="center" valign="middle">Placebo</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>(p&lt;0.01 versus placebo)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Basal Acid Output (mmol/hr)</td>
<td class="Rrule" align="center">0.4<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">2.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Stimulated Acid Output (mmol/hr)</td>
<td class="Rrule" align="center">0.6<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">13.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;3</td>
<td class="Rrule" align="center">65<a href="#footnote-2" class="Sup">*</a>
</td>
<td class="Rrule" align="center">10</td>
</tr>
</tbody>
</table>
<p>Compared to placebo, ACIPHEX, 10 mg, 20 mg, and 40 mg, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall. In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity. The ability of rabeprazole to cause a dose-related decrease in mean intragastric acidity is illustrated below.</p>
<a name="table4"></a><table width="75%">
<caption><span>TABLE 4 AUC ACIDITY (MMOL∙HR/L) ACIPHEX VERSUS PLACEBO ON DAY 7 OF ONCE DAILY DOSING (MEAN±SD)</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="4">Treatment</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">AUC interval<br>(hrs)</th>
<th class="Rrule Toprule" align="center">10 mg RBP<br>(N=24)</th>
<th class="Rrule Toprule" align="center">20 mg RBP<br>(N=24)</th>
<th class="Rrule Toprule" align="center">40 mg RBP<br>(N=24)</th>
<th class="Rrule Toprule" align="center">Placebo<br>(N=24)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>(p&lt;0.001 versus placebo)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">08:00 – 13:00</td>
<td class="Rrule" align="center">19.6±21.5<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">12.9±23<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">7.6±14.7<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">91.1±39.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">13:00 – 19:00</td>
<td class="Rrule" align="center">5.6±9.7<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">8.3±29.8<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">1.3±5.2<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">95.5±48.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">19:00 – 22:00</td>
<td class="Rrule" align="center">0.1±0.1<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0.1±0.06<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0.0±0.02<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">11.9±12.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">22:00 – 08:00</td>
<td class="Rrule" align="center">129.2±84<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">109.6±67.2<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">76.9±58.4<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">479.9±165</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AUC 0-24 hours</td>
<td class="Rrule" align="center">155.5±90.6<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">130.9±81<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">85.8±64.3<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">678.5±216</td>
</tr>
</tbody>
</table>
<p>After administration of 20 mg ACIPHEX Tablets once daily for eight days, the mean percent of time that gastric pH&gt;3 or gastric pH&gt;4 after a single dose (Day 1) and multiple doses (Day 8) was significantly greater than placebo (see table below). The decrease in gastric acidity and the increase in gastric pH observed with 20 mg ACIPHEX Tablets administered once daily for eight days were compared to the same parameters for placebo, as illustrated below:</p>
<a name="table5"></a><table width="75%">
<caption><span>TABLE 5 GASTRIC ACID PARAMETERS ACIPHEX ONCE DAILY DOSING VERSUS PLACEBO ON DAY 1 AND DAY 8</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">ACIPHEX 20 mg QD</th>
<th class="Rrule" align="center" colspan="2">Placebo</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule Toprule" align="center">Day 1</th>
<th class="Rrule Toprule" align="center">Day 8</th>
<th class="Rrule Toprule" align="center">Day 1</th>
<th class="Rrule Toprule" align="center">Day 8</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>(p&lt;0.001 versus placebo)</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>No inferential statistics conducted for this parameter.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Gastric pH was measured every hour over a 24-hour period.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Mean AUC<span class="Sub">0-24</span> Acidity</td>
<td class="Rrule" align="center">340.8<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">176.9<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">925.5</td>
<td class="Rrule" align="center">862.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Median trough pH (23-hr)<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3.77</td>
<td class="Rrule" align="center">3.51</td>
<td class="Rrule" align="center">1.27</td>
<td class="Rrule" align="center">1.38</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;3<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">54.6<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">68.7<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">19.1</td>
<td class="Rrule" align="center">21.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">% Time Gastric pH&gt;4<a href="#footnote-6" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">44.1<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">60.3<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">7.6</td>
<td class="Rrule" align="center">11.0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Effects on Esophageal Acid Exposure</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) and moderate to severe esophageal acid exposure, ACIPHEX 20 mg and 40 mg tablets per day decreased 24-hour esophageal acid exposure. After seven days of treatment, the percentage of time that esophageal pH&lt;4 decreased from baselines of 24.7% for 20 mg and 23.7% for 40 mg, to 5.1% and 2.0%, respectively. Normalization of 24-hour intraesophageal acid exposure was correlated to gastric pH&gt;4 for at least 35% of the 24-hour period; this level was achieved in 90% of subjects receiving ACIPHEX 20 mg and in 100% of subjects receiving ACIPHEX 40 mg. With ACIPHEX 20 mg and 40 mg per day, significant effects on gastric and esophageal pH were noted after one day of treatment, and more pronounced after seven days of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Effects on Serum Gastrin</span></p>
<p>In patients given daily doses of ACIPHEX for up to eight weeks to treat ulcerative or <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> and in patients treated for up to 52 weeks to prevent recurrence of disease the median fasting gastrin level increased in a dose-related manner. The group median values stayed within the normal range.</p>
<p>In a group of subjects treated daily with ACIPHEX 20 mg tablets for 4 weeks a doubling of mean serum gastrin concentrations were observed. Approximately 35% of these treated subjects developed serum gastrin concentrations above the upper limit of normal. In a study of CYP2C19 genotyped subjects in Japan, poor metabolizers developed statistically significantly higher serum gastrin concentrations than extensive metabolizers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Effects on Enterochromaffin-like (ECL) Cells</span></p>
<p>Increased serum gastrin secondary to antisecretory agents stimulates proliferation of gastric ECL cells which, over time, may result in ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in rats and mice and gastric carcinoids in rats, especially in females [<span class="Italics">see <a href="#S13.1">Nonclinical Toxicology (13.1)</a></span>].</p>
<p>In over 400 patients treated with ACIPHEX Tablets (10 or 20 mg/day) for up to one year, the incidence of ECL cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> increased with time and dose, which is consistent with the pharmacological action of the proton-pump inhibitor. No patient developed the adenomatoid, dysplastic or neoplastic changes of ECL cells in the gastric mucosa. No patient developed the <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span> observed in rats.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Underline">Endocrine Effects</span></p>
<p>Studies in humans for up to one year have not revealed clinically significant effects on the endocrine system. In healthy male volunteers treated with ACIPHEX for 13 days, no clinically relevant changes have been detected in the following endocrine parameters examined: 17β-estradiol, thyroid stimulating hormone, tri-iodothyronine, thyroxine, thyroxine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteotrophic hormone, prolactin, somatotrophic hormone, dehydroepiandrosterone, cortisol-binding globulin, and urinary 6β-hydroxycortisol, serum testosterone and circadian cortisol profile.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Underline">Other Effects</span></p>
<p>In humans treated with ACIPHEX for up to one year, no systemic effects have been observed on the central nervous, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems. No data are available on long-term treatment with ACIPHEX and ocular effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Underline">Microbiology</span></p>
<p>The following <span class="Italics">in vitro</span> data are available but the clinical significance is unknown.</p>
<p>Rabeprazole sodium, amoxicillin and clarithromycin as a three drug regimen has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Helicobacter pylori in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Italics"><a href="#S14">Clinical Studies (14)</a></span> and <span class="Italics"><a href="#S1">Indications and Usage (1)</a></span> sections.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.8"></a><p></p>
<p class="First"><span class="Underline">Helicobacter pylori</span></p>
<p>Susceptibility testing of <span class="Italics">H. pylori</span> isolates was performed for amoxicillin and clarithromycin using agar dilution methodology<span class="Sup">1</span>, and <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs) were determined.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control micro-organisms to control the technical aspects of the laboratory procedures.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.9"></a><p></p>
<p class="First"><span class="Underline">Incidence of Antibiotic-Resistant Organisms Among Clinical Isolates</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.9.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pretreatment Resistance:</span> Clarithromycin pretreatment resistance rate (MIC ≥1 μg/mL) to <span class="Italics">H. pylori</span> was 9% (51/ 560) at baseline in all treatment groups combined. A total of &gt;99% (558/560) of patients had <span class="Italics">H. pylori</span> isolates which were considered to be susceptible (MIC ≤0.25 μg/mL) to amoxicillin at baseline. Two patients had baseline <span class="Italics">H. pylori</span> isolates with an amoxicillin MIC of 0.5 μg/mL.</p>
<p>For susceptibility testing information about <span class="Italics">Helicobacter pylori</span>, <span class="Italics">see Microbiology section in prescribing information for clarithromycin and amoxicillin.</span></p>
<a name="table6"></a><table width="75%">
<caption><span>TABLE 6 CLARITHROMYCIN SUSCEPTIBILITY TEST RESULTS AND CLINICAL/BACTERIOLOGIC OUTCOMES<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>FOR A THREE DRUG REGIMEN (RABEPRAZOLE 20 MG TWICE DAILY, AMOXICILLIN 1000 MG TWICE DAILY, AND CLARITHROMYCIN 500 MG TWICE DAILY FOR 7 OR 10 DAYS)</span></caption>
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="10%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Days of RAC Therapy</th>
<th class="Rrule" align="center" rowspan="2">Clarithromycin Pretreatment Results</th>
<th class="Rrule" align="center" rowspan="2">Total Number</th>
<th class="Rrule" align="center" rowspan="2">
<span class="Italics">H. pylori</span> Negative (Eradicated)</th>
<th class="Rrule" align="center" colspan="4">
<span class="Italics">H. pylori</span> Positive (Persistent) Post-Treatment Susceptibility Results</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">S<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</th>
<th class="Rrule Toprule" align="center">I<a href="#footnote-8" class="Sup">†</a>
</th>
<th class="Rrule Toprule" align="center">R<a href="#footnote-8" class="Sup">†</a>
</th>
<th class="Rrule Toprule" align="center">No MIC</th>
</tr>
</thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Includes only patients with pretreatment and post-treatment clarithromycin susceptibility test results.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Susceptible (S) MIC ≤0.25 μg/mL, Intermediate (I) MIC = 0.5 μg/mL, Resistant (R) MIC ≥1 μg/mL</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">Susceptible<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">129</td>
<td class="Rrule" align="center">103</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">23</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">Intermediate<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">7</td>
<td class="Rrule" align="center">Resistant<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">Susceptible<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">133</td>
<td class="Rrule" align="center">111</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">Intermediate<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">10</td>
<td class="Rrule" align="center">Resistant<a href="#footnote-8" class="Sup">†</a>
</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">3</td>
</tr>
</tbody>
</table>
<p>Patients with persistent <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following rabeprazole, amoxicillin, and clarithromycin therapy will likely have clarithromycin resistant clinical isolates. Therefore, clarithromycin susceptibility testing should be done when possible. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.9.2"></a><p></p>
<p class="First"><span class="Italics">Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes:</span> In the U.S. multicenter study, a total of &gt;99% (558/560) of patients had <span class="Italics">H. pylori</span> isolates which were considered to be susceptible (MIC ≤0.25 μg/mL) to amoxicillin at baseline. The other 2 patients had baseline <span class="Italics">H. pylori</span> isolates with an amoxicillin MIC of 0.5 μg/mL, and both isolates were clarithromycin-resistant at baseline; in one case the <span class="Italics">H. pylori</span> was eradicated. In the 7- and 10-day treatment groups 75% (107/145) and 79% (112/142), respectively, of the patients who had pretreatment amoxicillin susceptible MICs (≤0.25 μg/mL) were eradicated of <span class="Italics">H. pylori.</span> No patients developed amoxicillin-resistant <span class="Italics">H. pylori</span> during therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">ACIPHEX Delayed-Release Tablets and Delayed-Release granules in the capsule formulation are enteric-coated to allow rabeprazole sodium, which is acid labile, to pass through the stomach relatively intact.</p>
<p>After oral administration of 20 mg ACIPHEX tablet, peak plasma concentrations (C<span class="Sub">max</span>) of rabeprazole occur over a range of 2.0 to 5.0 hours (T<span class="Sub">max</span>). The rabeprazole C<span class="Sub">max</span> and AUC are linear over an oral dose range of 10 mg to 40 mg. There is no appreciable accumulation when doses of 10 mg to 40 mg are administered every 24 hours; the pharmacokinetics of rabeprazole is not altered by multiple dosing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption:</span> Absolute bioavailability for a 20 mg oral tablet of rabeprazole (compared to intravenous administration) is approximately 52%. When ACIPHEX Tablets are administered with a high fat meal, T<span class="Sub">max</span> is variable; which concomitant food intake may delay the absorption up to 4 hours or longer. However, the C<span class="Sub">max</span> and the extent of rabeprazole absorption (AUC) are not significantly altered. Thus ACIPHEX tablets may be taken without regard to timing of meals.</p>
<p>After oral administration to healthy adults of 10 mg ACIPHEX granules sprinkled on applesauce under fasting condition, median time (T<span class="Sub">max</span>) to peak plasma concentrations (C<span class="Sub">max</span>) of rabeprazole was 2.5 hours and ranged 1.0 to 6.5 hours. The plasma half-life of rabeprazole ranges from 1 to 2 hours.</p>
<p>In healthy adults, a concomitant high fat meal delayed the absorption of rabeprazole from ACIPHEX granules sprinkled on one tablespoon of applesauce resulting in the median T<span class="Sub">max </span>of 4.5 hours and decreased the C<span class="Sub">max</span> and AUC<span class="Sub">last</span> on average by 55% and 33%, respectively. ACIPHEX granules should be taken before a meal.</p>
<p>When 10 mg ACIPHEX granules administered under fasting conditions to healthy adults on one tablespoon (15mL) of applesauce, one tablespoon (15mL) of yogurt, or when mixed with a small amount (5mL) of liquid infant formula; the type of soft food did not significantly affect T<span class="Sub">max</span>, C<span class="Sub">max</span> and AUC of rabeprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution:</span> Rabeprazole is 96.3% bound to human plasma proteins.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism:</span> Rabeprazole is extensively metabolized. A significant portion of rabeprazole is metabolized via systemic nonenzymatic reduction to a thioether compound. Rabeprazole is also metabolized to sulphone and desmethyl compounds via cytochrome P450 in the liver. The thioether and sulphone are the primary metabolites measured in human plasma. These metabolites were not observed to have significant antisecretory activity. <span class="Italics">In vitro</span> studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole. CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g. 3 to 5% of Caucasians and 17 to 20% of Asians). Rabeprazole metabolism is slow in these sub-populations, therefore, they are referred to as poor metabolizers of the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination:</span> Following a single 20 mg oral dose of <span class="Sup">14</span>C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites. The remainder of the dose was recovered in the feces. Total recovery of radioactivity was 99.8%. No unchanged rabeprazole was recovered in the urine or feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Geriatric:</span> In 20 healthy elderly subjects administered 20 mg rabeprazole tablet once daily for seven days, AUC values approximately doubled and the C<span class="Sub">max</span> increased by 60% compared to values in a parallel younger control group. There was no evidence of drug accumulation after once daily administration [<span class="Italics">see <a href="#S8.5">Use in Specific Populations (8.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Pediatric:</span> The pharmacokinetics of rabeprazole was studied in pediatric patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> aged up to 16 years in four separate clinical studies.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Patients 12 to 16 Years of Age</span></p>
<p>The pharmacokinetics of rabeprazole was studied in 12 adolescent patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 12 to 16 years of age, in a multicenter study. Patients received rabeprazole 20 mg tablets once daily for five or seven days. An approximate 40% increase in exposure was noted following 5 to 7 days of dosing compared with the exposure after 1 day dosing. Pharmacokinetic parameters in adolescent patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 12 to 16 years of age were within the range observed in healthy adult volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Patients 1 to 11 Years of Age</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 1 to 11 years of age, following once daily administration of rabeprazole granules at doses from 0.14 to 1 mg/kg, the median time to peak plasma concentration ranged 2-4 hours and the half-life was about 2.5 hours. No appreciable accumulation was noted following 5 days of dosing compared to exposure after a single dose.</p>
<p>Based on population pharmacokinetic analysis, over the body weight range from 7 to 77.3 kg, the apparent rabeprazole clearance increased from 8.0 to 13.5 L/hr, an increase of 68.8%.</p>
<p>The mean estimated total exposure i.e. AUC after a 10 mg dose of ACIPHEX Sprinkle in patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> 1 to 11 years of age is comparable to a 10 mg dose of ACIPHEX Tablets in adolescents and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3"></a><p></p>
<p class="First"><span class="Italics">Patients &lt;1 Year Old</span></p>
<p>[<span class="Italics">See <a href="#S8.4">Pediatric Use (8.4)</a>.</span>]</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline">Gender and Race:</span> In analyses adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and height, rabeprazole pharmacokinetics showed no clinically significant differences between male and female subjects. In studies that used different formulations of rabeprazole, AUC<span class="Sub">0-∞</span> values for healthy Japanese men were approximately 50-60% greater than values derived from pooled data from healthy men in the United States.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span>:</span> In 10 patients with stable end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring maintenance hemodialysis (creatinine clearance ≤5 mL/min/1.73 m<span class="Sup">2</span>), no clinically significant differences were observed in the pharmacokinetics of rabeprazole after a single 20 mg oral dose when compared to 10 healthy volunteers [<span class="Italics">see <a href="#S2.9">Dosage and Administration (2.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span>:</span> In a single dose study of 10 patients with chronic mild to moderate compensated cirrhosis of the liver who were administered a 20 mg dose of rabeprazole, AUC<span class="Sub">0-24</span> was approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance was decreased to less than half compared to values in healthy men.</p>
<p>In a multiple dose study of 12 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> administered 20 mg rabeprazole once daily for eight days, AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> values increased approximately 20% compared to values in healthy age- and gender-matched subjects. These increases were not statistically significant.</p>
<p>No information exists on rabeprazole disposition in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Please refer to the <span class="Italics"><a href="#S2.9">Dosage and Administration (2.9)</a></span> for information on dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.10"></a><p></p>
<p class="First"><span class="Underline">Combined Administration with Antimicrobials:</span> Sixteen healthy volunteers genotyped as extensive metabolizers with respect to CYP2C19 were given 20 mg rabeprazole sodium, 1000 mg amoxicillin, 500 mg clarithromycin, or all 3 drugs in a four-way crossover study. Each of the four regimens was administered twice daily for 6 days. The AUC and C<span class="Sub">max </span>for clarithromycin and amoxicillin were not different following combined administration compared to values following single administration. However, the rabeprazole AUC and C<span class="Sub">max</span> increased by 11% and 34%, respectively, following combined administration. The AUC and C<span class="Sub">max</span> for 14-hydroxyclarithromycin (active metabolite of clarithromycin) also increased by 42% and 46%, respectively. This increase in exposure to rabeprazole and 14-hydroxyclarithromycin is not expected to produce safety concerns.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.11"></a><p></p>
<p class="First"><span class="Underline">Concomitant Use with Clopidogrel: </span> Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects including CYP2C19 extensive and intermediate metabolizers receiving once daily administration of clopidogrel 75 mg concomitantly with placebo or with ACIPHEX 20 mg (n=36), for 7 days was conducted. The mean AUC of the active metabolite of clopidogrel was reduced by approximately 12% (mean AUC ratio was 88%, with 90% CI of 81.7 to 95.5%) when ACIPHEX was coadministered compared to administration of clopidogrel with placebo.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In an 88/104-week carcinogenicity study in CD-1 mice, rabeprazole at oral doses up to 100 mg/kg/day did not produce any increased tumor occurrence. The highest tested dose produced a systemic exposure to rabeprazole (AUC) of 1.40 μg∙hr/mL which is 1.6 times the human exposure (plasma AUC<span class="Sub">0-∞</span> = 0.88 μg∙hr/mL) at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> (20 mg/day). In a 28-week carcinogenicity study in p53<span class="Sup">+/-</span> transgenic mice, rabeprazole at oral doses of 20, 60, and 200 mg/kg/day did not cause an increase in the incidence rates of tumors but produced gastric mucosal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> at all doses. The systemic exposure to rabeprazole at 200 mg/kg/day is about 17-24 times the human exposure at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. In a 104-week carcinogenicity study in Sprague-Dawley rats, males were treated with oral doses of 5, 15, 30 and 60 mg/kg/day and females with 5, 15, 30, 60 and 120 mg/kg/day. Rabeprazole produced gastric enterochromaffin-like (ECL) cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in male and female rats and ECL cell <span class="product-label-link" type="condition" conceptid="4304399" conceptname="Carcinoid tumor">carcinoid tumors</span> in female rats at all doses including the lowest tested dose. The lowest dose (5 mg/kg/day) produced a systemic exposure to rabeprazole (AUC) of about 0.1 μg∙hr/mL which is about 0.1 times the human exposure at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>. In male rats, no treatment related tumors were observed at doses up to 60 mg/kg/day producing a rabeprazole plasma exposure (AUC) of about 0.2 μg∙hr/mL (0.2 times the human exposure at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>).</p>
<p>Rabeprazole was positive in the Ames test, the Chinese hamster ovary cell (CHO/HGPRT) forward gene mutation test and the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell (L5178Y/TK+/–) forward gene mutation test. Its demethylated-metabolite was also positive in the Ames test. Rabeprazole was negative in the <span class="Italics">in vitro</span> Chinese hamster lung cell chromosome aberration test, the <span class="Italics">in vivo</span> mouse micronucleus test, and the <span class="Italics">in vivo</span> and <span class="Italics">ex vivo</span> rat hepatocyte unscheduled DNA synthesis (UDS) tests.</p>
<p>Rabeprazole at intravenous doses up to 30 mg/kg/day (plasma AUC of 8.8 μg∙hr/mL, about 10 times the human exposure at the recommended dose for <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) was found to have no effect on fertility and reproductive performance of male and female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Studies in juvenile and young adult rats and dogs were performed. In juvenile animal studies rabeprazole sodium was administered orally to rats for up to 5 weeks and to dogs for up to 13 weeks, each commencing on Day 7 post-partum and followed by a 13-week recovery period. Rats were dosed at 5, 25 or 150 mg/kg/day and dogs were dosed at 3, 10 or 30 mg/kg/day. The data from these studies were comparable to those reported for young adult animals. Pharmacologically mediated changes, including increased serum gastrin levels and stomach changes, were observed at all dose levels in both rats and dogs. These observations were reversible over the 13-week recovery periods. Although body weights and/or crownrump lengths were minimally decreased during dosing, no effects on the development parameters were noted in either juvenile rats or dogs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">In a U.S., multicenter, randomized, double-blind, placebo-controlled study, 103 patients were treated for up to eight weeks with placebo, 10 mg, 20 mg or 40 mg ACIPHEX QD. For this and all studies of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> healing, only patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> symptoms and at least grade 2 <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> (modified Hetzel-Dent grading scale) were eligible for entry. Endoscopic healing was defined as grade 0 or 1. Each rabeprazole dose was significantly superior to placebo in producing endoscopic healing after four and eight weeks of treatment. The percentage of patients demonstrating endoscopic healing was as follows:</p>
<a name="table7"></a><table width="75%">
<caption><span>TABLE 7 HEALING OF EROSIVE OR ULCERATIVE <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GASTROESOPHAGEAL REFLUX DISEASE</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) PERCENTAGE OF PATIENTS HEALED</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Week</th>
<th class="Rrule" align="center">10 mg ACIPHEX QD<br> N=27</th>
<th class="Rrule" align="center">20 mg ACIPHEX QD<br> N=25</th>
<th class="Rrule" align="center">40 mg ACIPHEX QD<br> N=26</th>
<th class="Rrule" align="center">Placebo<br> N=25</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>(p&lt;0.001 versus placebo)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">63%<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">56%<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">54%<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">93%<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">84%<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">85%<a href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">12%</td>
</tr>
</tbody>
</table>
<p>In addition, there was a statistically significant difference in favor of the ACIPHEX 10 mg, 20 mg, and 40 mg doses compared to placebo at Weeks 4 and 8 regarding complete resolution of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> frequency (p≤0.026). All ACIPHEX groups reported significantly greater rates of complete resolution of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> severity compared to placebo at Weeks 4 and 8 (p≤0.036). Mean reductions from baseline in daily antacid dose were statistically significant for all ACIPHEX groups when compared to placebo at both Weeks 4 and 8 (p≤0.007).</p>
<p>In a North American multicenter, randomized, double-blind, active-controlled study of 336 patients, ACIPHEX was statistically superior to ranitidine with respect to the percentage of patients healed at endoscopy after four and eight weeks of treatment (see table below):</p>
<a name="table8"></a><table width="60%">
<caption><span>TABLE 8 HEALING OF EROSIVE OR ULCERATIVE <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GASTROESOPHAGEAL REFLUX DISEASE</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) PERCENTAGE OF PATIENTS HEALED</span></caption>
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Week</th>
<th class="Rrule" align="center">ACIPHEX 20 mg QD<br> N=167</th>
<th class="Rrule" align="center">Ranitidine 150 mg QID<br> N=169</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>(p&lt;0.001 versus ranitidine)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">59%<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a>
</td>
<td class="Rrule" align="center">36%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">8</td>
<td class="Rrule" align="center">87%<a href="#footnote-10" class="Sup">*</a>
</td>
<td class="Rrule" align="center">66%</td>
</tr>
</tbody>
</table>
<p>ACIPHEX 20 mg once daily was significantly more effective than ranitidine 150 mg QID in the percentage of patients with complete resolution of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> at Weeks 4 and 8 (p&lt;0.001). ACIPHEX 20 mg once daily was also more effective in complete resolution of daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> (p≤0.025), and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> (p≤0.012) at both Weeks 4 and 8, with significant differences by the end of the first week of the study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Long-term Maintenance of Healing of Erosive or Ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">The long-term maintenance of healing in patients with erosive or ulcerative <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> previously healed with gastric antisecretory therapy was assessed in two U.S., multicenter, randomized, double-blind, placebo-controlled studies of identical design of 52 weeks duration. The two studies randomized 209 and 285 patients, respectively, to receive either 10 mg or 20 mg of ACIPHEX QD or placebo. As demonstrated in the tables below, ACIPHEX was significantly superior to placebo in both studies with respect to the maintenance of healing of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> and the proportions of patients remaining free of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms at 52 weeks:</p>
<a name="table9"></a><table width="75%">
<caption><span>TABLE 9 PERCENT OF PATIENTS IN ENDOSCOPIC REMISSION</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center">ACIPHEX <br>10 mg</th>
<th class="Rrule" align="center">ACIPHEX <br>20 mg</th>
<th class="Rrule" align="center">Placebo</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>(p&lt;0.001 versus placebo)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Study 1</td>
<td class="Rrule" align="center">N=66</td>
<td class="Rrule" align="center">N=67</td>
<td class="Rrule" align="center">N=70</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 4</td>
<td class="Rrule" align="center">83%<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">96%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">44%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 13</td>
<td class="Rrule" align="center">79%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">93%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">39%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 26</td>
<td class="Rrule" align="center">77%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">93%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">31%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 39</td>
<td class="Rrule" align="center">76%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">91%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 52</td>
<td class="Rrule" align="center">73%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">90%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">29%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Study 2</td>
<td class="Rrule" align="center">N=93</td>
<td class="Rrule" align="center">N=93</td>
<td class="Rrule" align="center">N=99</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 4</td>
<td class="Rrule" align="center">89%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">94%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">40%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 13</td>
<td class="Rrule" align="center">86%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">91%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">33%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 26</td>
<td class="Rrule" align="center">85%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">89%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 39</td>
<td class="Rrule" align="center">84%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">88%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">29%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 52</td>
<td class="Rrule" align="center">77%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">86%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">29%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">COMBINED STUDIES</td>
<td class="Rrule" align="center">N=159</td>
<td class="Rrule" align="center">N=160</td>
<td class="Rrule" align="center">N=169</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 4</td>
<td class="Rrule" align="center">87%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">94%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">42%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 13</td>
<td class="Rrule" align="center">83%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">92%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">36%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 26</td>
<td class="Rrule" align="center">82%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">91%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">31%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">Week 39</td>
<td class="Rrule" align="center">81%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">89%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center">Week 52</td>
<td class="Rrule" align="center">75%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">87%<a href="#footnote-11" class="Sup">*</a>
</td>
<td class="Rrule" align="center">29%</td>
</tr>
</tbody>
</table>
<a name="table10"></a><table width="75%">
<caption><span>TABLE 10 PERCENT OF PATIENTS WITHOUT RELAPSE IN <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> FREQUENCY AND DAYTIME AND NIGHTTIME <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> SEVERITY AT WEEK 52</span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">ACIPHEX <br>10 mg</th>
<th class="Rrule" align="center">ACIPHEX<br> 20 mg</th>
<th class="Rrule" align="center">Placebo</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>p≤0.001 versus placebo</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">†</a></dt>
<dd>0.001&lt;p&lt;0.05 versus placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> Frequency</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Study 1</td>
<td class="Rrule" align="center">46/55<br>(84%)<a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">48/52<br>(92%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">17/45<br>(38%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Study 2</td>
<td class="Rrule" align="center">50/72<br>(69%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">57/72<br>(79%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">22/79<br>(28%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> Severity</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Study 1</td>
<td class="Rrule" align="center">61/64<br>(95%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">60/62<br>(97%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">42/61<br>(69%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Study 2</td>
<td class="Rrule" align="center">73/84<br>(87%)<a name="footnote-reference-13" href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center">82/87<br>(94%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">67/90<br>(74%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span> Severity</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Study 1</td>
<td class="Rrule" align="center">57/61<br>(93%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">60/61<br>(98%)<a href="#footnote-12" class="Sup">*</a>
</td>
<td class="Rrule" align="center">37/56<br>(66%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Study 2</td>
<td class="Rrule" align="center">67/80<br>(84%)</td>
<td class="Rrule" align="center">79/87<br>(91%)<a href="#footnote-13" class="Sup">†</a>
</td>
<td class="Rrule" align="center">64/87<br>(74%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Treatment of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adults</h2>
<p class="First">Two U.S., multicenter, double-blind, placebo controlled studies were conducted in 316 adult patients with daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. Patients reported 5 or more periods of moderate to very severe <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> during the placebo treatment phase the week prior to randomization. Patients were confirmed by endoscopy to have no <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span>.</p>
<p>The percentage of <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> free daytime and/or nighttime periods was greater with ACIPHEX 20 mg compared to placebo over the 4 weeks of study in Study RAB-USA-2 (47% vs. 23%) and Study RAB-USA-3 (52% vs. 28%). The mean decreases from baseline in average daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> scores were significantly greater for ACIPHEX 20 mg as compared to placebo at week 4. Graphical displays depicting the daily mean daytime and nighttime scores are provided in Figures 2 to 5.</p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">FIGURE 2: MEAN DAYTIME <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> SCORES RAB-USA-2</td></tr>
<tr><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-02.jpg"></td></tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">FIGURE 3: MEAN NIGHTTIME <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> SCORES RAB-USA-2</td></tr>
<tr><td align="center"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-03.jpg"></td></tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">FIGURE 4: MEAN DAYTIME <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> SCORES RAB-USA-3</td></tr>
<tr><td align="center"><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-04.jpg"></td></tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">FIGURE 5: MEAN NIGHTTIME <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">HEARTBURN</span> SCORES RAB-USA-3</td></tr>
<tr><td align="center"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-05.jpg"></td></tr>
</tbody>
</table>
<p>In addition, the combined analysis of these two studies showed ACIPHEX 20 mg significantly improved other <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>-associated symptoms (<span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">belching</span> and <span class="product-label-link" type="condition" conceptid="40481819" conceptname="Early satiety">early satiety</span>) by week 4 compared with placebo (all p values &lt;0.005).</p>
<p>ACIPHEX 20 mg also significantly reduced daily antacid consumption versus placebo over 4 weeks (p&lt;0.001).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcers</span> in Adults</h2>
<p class="First">In a U.S., randomized, double-blind, multicenter study assessing the effectiveness of 20 mg and 40 mg of ACIPHEX QD versus placebo for healing endoscopically defined <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, 100 patients were treated for up to four weeks. ACIPHEX was significantly superior to placebo in producing healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. The percentages of patients with endoscopic healing are presented below:</p>
<a name="table11"></a><table width="75%">
<caption><span>TABLE 11 HEALING OF <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCERS</span> PERCENTAGE OF PATIENTS HEALED</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Week</th>
<th class="Rrule" align="center">ACIPHEX 20 mg QD<br> N=34</th>
<th class="Rrule" align="center">ACIPHEX 40 mg QD<br> N=33</th>
<th class="Rrule" align="center">Placebo<br> N=33</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>p≤0.001 versus placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">44%</td>
<td class="Rrule" align="center">42%</td>
<td class="Rrule" align="center">21%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">79%<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">91%<a href="#footnote-14" class="Sup">*</a>
</td>
<td class="Rrule" align="center">39%</td>
</tr>
</tbody>
</table>
<p>At Weeks 2 and 4, significantly more patients in the ACIPHEX 20 and 40 mg groups reported complete resolution of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> frequency (p≤0.018), daytime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> severity (p≤0.023), and nighttime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> severity (p≤0.035) compared with placebo patients. The only exception was the ACIPHEX 40 mg group versus placebo at Week 2 for <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> frequency (p=0.094). Significant differences in resolution of daytime and nighttime <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> were noted in both ACIPHEX groups relative to placebo by the end of the first week of the study. Significant reductions in daily antacid use were also noted in both ACIPHEX groups compared to placebo at Weeks 2 and 4 (p&lt;0.001).</p>
<p>An international randomized, double-blind, active-controlled trial was conducted in 205 patients comparing 20 mg ACIPHEX QD with 20 mg omeprazole QD. The study was designed to provide at least 80% power to exclude a difference of at least 10% between ACIPHEX and omeprazole, assuming four-week healing response rates of 93% for both groups. In patients with endoscopically defined <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> treated for up to four weeks, ACIPHEX was comparable to omeprazole in producing healing of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. The percentages of patients with endoscopic healing at two and four weeks are presented below:</p>
<a name="table12"></a><table width="75%">
<caption><span>TABLE 12 HEALING OF <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">DUODENAL ULCERS</span> PERCENTAGE OF PATIENTS HEALED</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Week</th>
<th class="Rrule" align="center">ACIPHEX 20 mg QD <br>N=102</th>
<th class="Rrule" align="center">Omeprazole 20 mg QD<br> N=103</th>
<th class="Rrule" align="center">95% Confidence Interval for the Treatment Difference<br>(ACIPHEX - Omeprazole)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">2</td>
<td class="Rrule" align="center">69%</td>
<td class="Rrule" align="center">61%</td>
<td class="Rrule" align="center">(–6%, 22%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">4</td>
<td class="Rrule" align="center">98%</td>
<td class="Rrule" align="center">93%</td>
<td class="Rrule" align="center">(–3%, 15%)</td>
</tr>
</tbody>
</table>
<p>ACIPHEX and omeprazole were comparable in providing complete resolution of symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5 <span class="Italics">Helicobacter pylori</span> Eradication in Patients with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic Ulcer Disease</span> or Symptomatic Non-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Disease in Adults</h2>
<p class="First">The U.S. multicenter study was a double-blind, parallel-group comparison of rabeprazole, amoxicillin, and clarithromycin for 3, 7, or 10 days vs. omeprazole, amoxicillin and clarithromycin for 10 days. Therapy consisted of rabeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (RAC) or omeprazole 20 mg twice daily, amoxicillin 1000 mg twice daily, and clarithromycin 500 mg twice daily (OAC). Patients with <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were stratified in a 1:1 ratio for those with <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> (active or a history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> in the past five years) [PUD] and those who were symptomatic but without <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> [NPUD], as determined by upper gastrointestinal endoscopy. The overall <span class="Italics">H. pylori</span> eradication rates, defined as negative <span class="Sup">13</span>C-UBT for <span class="Italics">H. pylori </span>≥6 weeks from the end of the treatment are shown in the following table. The eradication rates in the 7-day and 10-day RAC regimens were found to be similar to 10-day OAC regimen using either the Intent-to-Treat (ITT) or Per-Protocol (PP) populations. Eradication rates in the RAC 3-day regimen were inferior to the other regimens.</p>
<a name="table13"></a><table width="75%">
<caption><span>TABLE 13 HELICOBACTER PYLORI ERADICATION AT ≥6 WEEKS AFTER THE END OF TREATMENT</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Treatment Group Percent (%) of Patients Cured <br>(Number of Patients)</th>
<th class="Rrule" align="center">Difference <br>(RAC – OAC) <br>[95% Confidence Interval]</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>The 95% confidence intervals for the difference in eradication rates for 7-day RAC minus 10-day RAC are (- 9.3, 6.0) in the PP population and (- 9.0, 7.5) in the ITT population.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd>Patients were included in the analysis if they had <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> documented at baseline, defined as a positive <span class="Sup">13</span>C-UBT plus rapid urease test or culture and were not protocol violators. Patients who dropped out of the study due to an adverse event related to the study drug were included in the evaluable analysis as failures of therapy.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>Patients were included in the analysis if they had documented <span class="Italics">H. pylori</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at baseline as defined above and took at least one dose of study medication. All dropouts were included as failures of therapy.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"></td>
<td align="center"><span class="Bold">7-day RAC<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a></span></td>
<td align="center"><span class="Bold">10-day OAC</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Per Protocol<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a>
</td>
<td class="Rrule" align="center">84.3%<br>(N=166)</td>
<td class="Rrule" align="center">81.6%<br>(N=179)</td>
<td class="Rrule" align="center">2.8<br>[- 5.2, 10.7]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intent-to-Treat<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">77.3%<br>(N=194)</td>
<td class="Rrule" align="center">73.3%<br>(N=206)</td>
<td class="Rrule" align="center">4.0<br>[- 4.4, 12.5]</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"></td>
<td align="center"><span class="Bold">10-day RAC<a href="#footnote-15" class="Sup">*</a></span></td>
<td align="center"><span class="Bold">10-day OAC</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Per Protocol<a href="#footnote-16" class="Sup">†</a>
</td>
<td class="Rrule" align="center">86.0%<br>(N=171)</td>
<td class="Rrule" align="center">81.6%<br>(N=179)</td>
<td class="Rrule" align="center">4.4<br>[- 3.3, 12.1]</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intent-to-Treat<a href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">78.1%<br>(N=196)</td>
<td class="Rrule" align="center">73.3%<br>(N=206)</td>
<td class="Rrule" align="center">4.8<br>[- 3.6, 13.2]</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left"></td>
<td align="center"><span class="Bold">3-day RAC</span></td>
<td align="center"><span class="Bold">10-day OAC</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Per Protocol<a href="#footnote-16" class="Sup">†</a>
</td>
<td class="Rrule" align="center">29.9%<br>(N=167)</td>
<td class="Rrule" align="center">81.6%<br>(N=179)</td>
<td class="Rrule" align="center">- 51.6<br>[- 60.6, - 42.6]</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Intent-to-Treat<a href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">27.3%<br>(N=187)</td>
<td class="Rrule" align="center">73.3%<br>(N=206)</td>
<td class="Rrule" align="center">- 46.0<br>[- 54.8, - 37.2]</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults</h2>
<p class="First">Twelve patients with idiopathic gastric hypersecretion or Zollinger-Ellison syndrome have been treated successfully with ACIPHEX at doses from 20 to 120 mg for up to 12 months. ACIPHEX produced satisfactory inhibition of gastric acid secretion in all patients and complete resolution of signs and symptoms of acid-peptic disease where present. ACIPHEX also prevented recurrence of gastric hypersecretion and manifestations of acid-peptic disease in all patients. The high doses of ACIPHEX used to treat this small cohort of patients with gastric hypersecretion were well tolerated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.7"></a><a name="section-13.7"></a><p></p>
<h2>14.7 Pediatric <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.7.1"></a><p></p>
<p class="First"><span class="Italics">Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Adolescents 12 to 16 Years of Age</span></p>
<p>In a multicenter, randomized, open-label, parallel-group study, 111 adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> or suspected or endoscopically proven <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> were randomized and treated with either ACIPHEX 10 mg or ACIPHEX 20 mg once daily for up to 8 weeks for the evaluation of safety and efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.7.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in Pediatric Patients 1 to 11 Years of Age</span></p>
<p>The use of ACIPHEX Sprinkle in pediatric patients 1 to 11 years of age is supported by a two-part, multicenter, randomized, double-blind, parallel 2 dose arms clinical trial which was conducted in 127 pediatric patients with endoscopic and histologic evidence of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> prior to study treatment.</p>
<p>Part 1 was 12 weeks in duration. Patients were randomized to one of two rabeprazole dose levels based on body weight. Patients weighing 6.0 to 14.9 kg received either 5 or 10 mg rabeprazole, and those with body weight ≥15 kg received either 10 or 20 mg of rabeprazole. Part 2 was a 24-week double-blinded extension of Part 1 (on same dose assigned in Part 1). Endoscopic evaluations were performed at 12 weeks (Part 1) and 36 weeks (Part 2) to assess esophageal healing. No prespecified formal hypothesis testing was conducted.</p>
<p>For Part 1, rates of endoscopic healing were calculated and are shown in Table 14.</p>
<a name="table14"></a><table width="75%">
<caption><span>TABLE 14 SHORT-TERM (12-WEEK) HEALING RATES IN 1 to 11 YEAR OLD CHILDREN (PART 1)</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle">Endoscopic Classification of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> At Baseline</th>
<th class="Rrule" align="center" colspan="3">Healing Rate at 12 weeks</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule Toprule" align="center" colspan="2">Body Weight &lt;15 kg</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Body Weight ≥15 kg</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="left"></th>
<th class="Rrule" align="center">5 mg dose</th>
<th class="Rrule" align="center">10 mg dose</th>
<th class="Rrule" align="center">10 mg dose</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Hetzel-Dent score ≥2</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Hetzel-Dent score = 1</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Erosive<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>
</td>
<td class="Rrule" align="center">88%<br>(7/8)</td>
<td class="Rrule" align="center">83%<br>(5/6)</td>
<td class="Rrule" align="center">71%<br>(12/17)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Non-erosive<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">78%<br>(7/9)</td>
<td class="Rrule" align="center">100%<br>(10/10)</td>
<td class="Rrule" align="center">81%<br>(17/21)</td>
</tr>
</tbody>
</table>
<p>Of the 87 patients with healing in Part 1, 64 patients were enrolled into Part 2. The absence of a placebo group does not allow assessment of sustained efficacy through 36 weeks. Of the 52 patients with available data, healing was observed in 47 (90%) patients at 36 weeks.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. National Committee for Clinical Laboratory Standards. <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</span>—Fifth Edition. Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January 2000.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ACIPHEX 20 mg is supplied as delayed-release light yellow enteric-coated tablets. The name and strength, in mg, (ACIPHEX 20) is imprinted on one side.</p>
<dl>
<dt> </dt>
<dd>Bottles of 30 (NDC 62856-243-30)<br>Bottles of 90 (NDC 62856-243-90)<br>Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> Package of 100 (10 × 10) (NDC 62856-243-41)</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [<span class="Italics">see</span> USP Controlled Room Temperature]. Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15.2"></a><p></p>
<p class="First">ACIPHEX Sprinkle (5 mg) is supplied as transparent blue and opaque white capsules containing enteric coated granules. Identification and strength (ACX 5mg) are imprinted on the body of the capsule. An arrow (↑) imprint on the capsule cap indicates direction for opening a capsule.</p>
<p>Bottles of 30 (NDC 13551-205-01)</p>
<p>ACIPHEX Sprinkle (10 mg) is supplied as transparent yellow and opaque white capsules containing enteric coated granules. Identification and strength (ACX 10mg) are imprinted on the body of the capsule. An arrow (↑) imprint on the capsule cap indicates direction for opening a capsule.</p>
<p>Bottles of 30 (NDC 13551-210-01)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.3"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [<span class="Italics">see</span> USP Controlled Room Temperature]. Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#MG">FDA-approved patient labeling (Medication Guide</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">How to Take ACIPHEX</span></p>
<p>Patients should be cautioned that ACIPHEX Delayed-Release Tablets should be swallowed whole. The tablets should not be chewed, crushed, or split. ACIPHEX can be taken with or without food.</p>
<p>ACIPHEX Sprinkle Delayed-Release Capsules should be opened and the granule contents sprinkled on a small amount of soft food (e.g. applesauce, fruit or vegetable based baby food, or yogurt) or empty contents into a small amount of liquid (e.g. infant formula, apple juice, or pediatric electrolyte solution). Food or liquid should be at or below room temperature. The whole dose should be taken within 15 minutes of being sprinkled. The granules should not be chewed or crushed. The dose should be taken 30 minutes before a meal. Do not store mixture for future use.</p>
<p>Advise patient to immediately report and seek care for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> that does not improve. This may be a sign of <span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> [<span class="Italics">see <a href="#S5.3">Warnings and Precautions (5.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MG"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ACIPHEX<span class="Sup">®</span> (a-se-feks)<br>(rabeprazole sodium)<br>Delayed-Release Tablets</span></p>
<p><span class="Bold">ACIPHEX<span class="Sup">®</span> Sprinkle™ (a-se-feks spr-en-kle)<br>(rabeprazole sodium)<br>Delayed-Release Capsules</span></p>
<p>Read the Medication Guide that comes with ACIPHEX before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment.</p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about ACIPHEX?</span></p>
<p><span class="Bold">ACIPHEX may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</span></p>
<p><span class="Bold">ACIPHEX can cause serious side effects, including:</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>.</span> ACIPHEX may increase your risk of getting severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. This <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may be caused by an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (<span class="Italics">Clostridium difficile</span>) in your intestines.<br>Call your doctor right away if you have watery stool, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> that does not go away.</li>
<li>
<span class="Bold">Bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>.</span> People who take multiple daily doses of Proton Pump Inhibitor (PPI) medicines for a long period of time (1 year or longer) may have an increased risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the hip, wrist, or spine. You should take ACIPHEX exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> if you take ACIPHEX.</li>
</ul>
<p>ACIPHEX can have other serious side effects. See <span class="Bold">"<a href="#possible">What are the possible side effects of ACIPHEX?</a>"</span></p>
<p><span class="Bold">What is ACIPHEX?</span></p>
<p>ACIPHEX is a prescription medicine called a Proton Pump Inhibitor (PPI). ACIPHEX reduces the amount of acid in your stomach.</p>
<p>ACIPHEX is used in adults:</p>
<ul>
<li>for up to 8 weeks to heal acid-related damage to the lining of the esophagus (called <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">erosive esophagitis</span> or EE) and to relieve symptoms, such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. If needed, your doctor may decide to prescribe another 8 weeks of ACIPHEX.</li>
<li>to maintain the healing of the esophagus and relief of symptoms related to EE. It is not known if ACIPHEX is safe and effective if used longer than 12 months (1 year).</li>
<li>for 4 weeks to treat daytime and nighttime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and other symptoms that happen with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>).<br><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste, or burping.</li>
<li>for up to 4 weeks for the healing and relief of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. The duodenal area is the area where food passes when it leaves the stomach.</li>
<li>for 7 days with certain antibiotic medicines to treat an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by bacteria called <span class="Italics">H. pylori</span>. Sometimes <span class="Italics">H. pylori</span> bacteria can cause <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>. The <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> needs to be treated to prevent the <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> from coming back.</li>
<li>for the long-term treatment of conditions where your stomach makes too much acid. This includes a rare condition called Zollinger-Ellison syndrome.</li>
</ul>
<p>ACIPHEX is used in adolescents 12 years of age and older to treat symptoms of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux Disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) for up to 8 weeks.</p>
<p>ACIPHEX is used in children 1 to 11 years of age to treat <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> for up to 12 weeks.</p>
<p>ACIPHEX is not effective in treating symptoms of <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in children 1 month to 11 months of age.</p>
<p>ACIPHEX should not be used to treat <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span> in babies younger than 1 month of age.</p>
<p><span class="Bold">Who should not take ACIPHEX?</span></p>
<p><span class="Bold">Do not take ACIPHEX if you:</span></p>
<ul>
<li>are allergic to rabeprazole or any of the other ingredients in ACIPHEX. See the end of this Medication Guide for a complete list of ingredients in ACIPHEX.</li>
<li>are allergic to any other Proton Pump Inhibitor (PPI) medicine.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking ACIPHEX?</span></p>
<p><span class="Bold">Before you take ACIPHEX tell your doctor if you:</span></p>
<ul>
<li>have been told that you have low magnesium levels in your blood.</li>
<li>have liver problems.</li>
<li>have any allergies.</li>
<li>have any other medical conditions.</li>
<li>are pregnant or planning to become pregnant. It is not known if ACIPHEX can harm your unborn baby.</li>
<li>are breastfeeding. It is not known if ACIPHEX passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take ACIPHEX.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. </span>ACIPHEX may affect how other medicines work, and other medicines may affect how ACIPHEX works.</p>
<p>Especially tell your doctor if you take:</p>
<ul>
<li>atazanavir (Reyataz)</li>
<li>cyclosporine (Sandimmune, Neoral)</li>
<li>digoxin (Lanoxin)</li>
<li>ketoconazole (Nizoral)</li>
<li>warfarin (Coumadin)</li>
<li>theophylline (THEO-24 Thelair)</li>
<li>diazepam (Valium)</li>
<li>phenytoin (Dilantin)</li>
<li>an antibiotic that contains amoxicillin or clarithromycin</li>
<li>a "water pill" (diuretic)</li>
<li>methotrexate</li>
</ul>
<p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p>
<p>Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ACIPHEX?</span></p>
<ul>
<li>Take ACIPHEX exactly as prescribed. Your doctor will prescribe the dose that is right for you and your medical condition. Do not change your dose or stop taking ACIPHEX unless you talk to your doctor. Take ACIPHEX for as long as it is prescribed even if you feel better.</li>
<li>ACIPHEX is usually taken one time each day. Your doctor will tell you the time of day to take ACIPHEX, based on your medical condition.</li>
<li>
<span class="Bold">ACIPHEX Tablets</span> can be taken with or without food. Your doctor will tell you whether to take this medicine with or without food based on your medical condition.</li>
<li>Swallow each <span class="Bold">ACIPHEX Tablet</span> whole with water. <span class="Bold">Do not chew, crush, or split ACIPHEX Tablets</span>. Tell your doctor if you cannot swallow tablets whole.</li>
<li>
<span class="Bold">Take a dose of ACIPHEX Sprinkle Delayed- Release Capsules</span> as follows:<dl>
<dt>- </dt>
<dd>Take the dose 30 minutes before a meal.</dd>
<dt>- </dt>
<dd>Open the capsule and sprinkle the contents onto a small amount of soft food such as applesauce, fruit or vegetable based baby food, or yogurt. You may also empty the capsule contents into a small amount of infant formula, apple juice, or a pediatric electrolyte solution such as Pedialyte<span class="Sup">®</span>. The food or liquid that you use should be at or below room temperature.</dd>
<dt>- </dt>
<dd><span class="Bold">Swallow the entire mixture. Do not chew or crush the granules.</span></dd>
<dt>- </dt>
<dd>Take the entire dose <span class="Bold">within 15 minutes.</span> If you cannot take the dose within 15 minutes of preparing it, throw it away and prepare a new dose. Do not save it for use later.</dd>
</dl>
</li>
<li>If you miss a dose of ACIPHEX, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2 doses at the same time.</li>
<li>If you take too much ACIPHEX, call your doctor or Poison Control Center right away, or go to the nearest hospital emergency room.</li>
<li>Your doctor may prescribe antibiotic medicines with ACIPHEX to help treat a stomach <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and heal stomach (duodenal) <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> that are caused by bacteria called <span class="Italics">H. pylori</span>. Make sure you read the patient information that comes with an antibiotic before you start taking it.</li>
</ul>
<p><a name="possible"></a><span class="Bold">What are the possible side effects of ACIPHEX?</span></p>
<p>ACIPHEX can cause serious side effects, including:</p>
<ul>
<li><span class="Bold">See "<a href="#important">What is the most important information I should know about ACIPHEX?</a>"</span></li>
<li>
<span class="Bold">Low magnesium levels in your body.</span> This problem can be serious. Low magnesium can happen in some people who take a Proton Pump inhibitor (PPI) medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.<br>Tell your doctor right away if you have any of these symptoms:<dl>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>- </dt>
<dd>abnormal or fast heartbeat</dd>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span></dd>
<dt>- </dt>
<dd>jerking movements or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>)</dd>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span></dd>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the hands and feet</dd>
<dt>- </dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span></dd>
<dt>- </dt>
<dd>spasm of the voice box</dd>
</dl>
<br>Your doctor may check the level of magnesium in your body before you start taking ACIPHEX, during treatment, or if you will be taking ACIPHEX for a long period of time.</li>
</ul>
<p>The most common side effects with ACIPHEX include:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
</ul>
<p>The most common side effects with ACIPHEX in children include:</p>
<ul>
<li>stomach-area (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
</ul>
<p>Other side effects:</p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> Tell your doctor if you get any of the following symptoms with ACIPHEX:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li>face <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></li>
</ul>
<p>Your doctor may stop ACIPHEX if these symptoms happen.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the side effects of ACIPHEX. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ACIPHEX?</span></p>
<ul><li>Store ACIPHEX Tablets and ACIPHEX Sprinkle Delayed-Release Capsules in a dry place at room temperature between 68°F to 77°F (20°C to 25°C).</li></ul>
<p><span class="Bold">Keep ACIPHEX and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about ACIPHEX</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ACIPHEX for a condition for which it was not prescribed. Do not give ACIPHEX to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about ACIPHEX. If you would like more information, talk to your doctor. You can also ask your doctor or pharmacist for information about ACIPHEX that is written for healthcare professionals. For more information, go to http://www.aciphex.com/ or call 1-888-4-ACIPHEX.</p>
<p><span class="Bold">What are the ingredients in ACIPHEX?</span></p>
<p><span class="Bold">Active ingredient: </span>rabeprazole sodium</p>
<p><span class="Bold">ACIPHEX Delayed-Release Tablets inactive ingredients:</span> carnauba wax, crospovidone, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium stearate, mannitol, propylene glycol, sodium hydroxide, sodium stearyl fumarate, talc, and titanium dioxide. Iron oxide yellow is the coloring agent for the tablet coating. Iron oxide red is the ink pigment.</p>
<p><span class="Bold">ACIPHEX Sprinkle Delayed-Release Capsules inactive ingredients:</span> colloidal silicon dioxide, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, potassium chloride, FD&amp;C Blue No.2 Aluminum Lake (in the 5 mg capsule), FD&amp;C Yellow, No. 6 (in the 10 mg capsule), and gray printing ink.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>ACIPHEX<span class="Sup">®</span> Sprinkle™ is Distributed by<br>FSC Laboratories, Inc.<br>Charlotte, NC 28210</p>
<p>Revised June 2014</p>
<p>ACIPHEX<span class="Sup">®</span> is a registered trademark of Eisai R&amp;D Management Co., Ltd; ACIPHEX<span class="Sup">®</span> Sprinkle™ is a trademark of Eisai R&amp;D Management Co., Ltd, each of which is licensed to Eisai Inc. All brand names are the trademarks of their respective owners.</p>
<p>Revised June 2014<br>203229</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg Bottle Label</h1>
<p class="First">NDC 13551-205-01<br>Rx only</p>
<p><span class="Bold Italics">AcipHex<span class="Sup">®</span><br>Sprinkle</span>™</p>
<p><span class="Italics">(rabeprazole sodium)<br>Delayed-Release<br>Capsules</span></p>
<p><span class="Bold Italics">5 </span>mg</p>
<p><span class="Bold">FSC laboratories</span></p>
<p><span class="Italics">30 capsules</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label</h1>
<p class="First">NDC 13551-210-01<br>Rx only</p>
<p><span class="Bold Italics">AcipHex<span class="Sup">®</span><br>Sprinkle</span>™</p>
<p><span class="Italics">(rabeprazole sodium)<br>Delayed-Release<br>Capsules</span></p>
<p><span class="Bold Italics">10 </span>mg</p>
<p><span class="Bold">FSC laboratories</span></p>
<p><span class="Italics">30 capsules</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5a1edab0-a602-4786-9ef5-40063f9efdb4&amp;name=aciphex-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACIPHEX  		
					SPRINKLE</strong><br><span class="contentTableReg">rabeprazole sodium capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13551-205</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rabeprazole sodium</strong> (rabeprazole) </td>
<td class="formItem">rabeprazole sodium</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>diacetylated monoglycerides</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ethylcelluloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose (type h)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hypromellose Phthalate (24% Phthalate, 55 Cst)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carrageenan</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>potassium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>aluminum oxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (transparent) , WHITE (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACX;5mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13551-205-01</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204736</td>
<td class="formItem">10/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACIPHEX  		
					SPRINKLE</strong><br><span class="contentTableReg">rabeprazole sodium capsule, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:13551-210</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>rabeprazole sodium</strong> (rabeprazole) </td>
<td class="formItem">rabeprazole sodium</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Silicon Dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>diacetylated monoglycerides</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ethylcelluloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose (type h)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hypromellose Phthalate (24% Phthalate, 55 Cst)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium oxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carrageenan</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>potassium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Yellow No. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (transparent) , WHITE (opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (Oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACX;10mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:13551-210-01</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204736</td>
<td class="formItem">10/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>FSC Laboratories, Inc.
							(169886244)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8f36a957-8129-4f69-a57f-b60d485e04f8</div>
<div>Set id: 5a1edab0-a602-4786-9ef5-40063f9efdb4</div>
<div>Version: 1</div>
<div>Effective Time: 20140923</div>
</div>
</div> <div class="DistributorName">FSC Laboratories, Inc.</div></p>
</body></html>
